Overview
Access
/time_series
data via our API — starting from the
Basic plan and above.
Description
Intervacc AB is a dynamic player within the biotechnology sector, primarily focused on developing novel vaccines targeting animal health. The company's primary mission is to create advanced biologic solutions to combat infectious diseases in animals, thereby enhancing animal welfare and bolstering global veterinary practices. A notable feature of Intervacc AB's work is its emphasis on innovative vaccine technologies that leverage molecular biology and synthetic biotechnology. These efforts are particularly impactful in the veterinary pharmaceutical industry, addressing the needs of livestock farmers and pet owners alike by preventing diseases that could otherwise lead to significant economic losses and animal suffering. Operating within this niche yet critical industry, Intervacc AB contributes significantly to the advancement of animal health solutions worldwide, serving a crucial role in both food production sectors and pet care markets. By providing alternative prophylactic methods, the company aids in reducing the need for antibiotics, aligning with global health initiatives aimed at combating antibiotic resistance.
About
CEO
Mr. Jonas Sohlman
Employees
15
Address
Västertorpsvägen 135
Hägersten, 129 44
Hägersten, 129 44
Phone
46 8 12 01 06 00
Website
Instrument type
Common stock
Sector
Healthcare
Industry
Biotechnology
Country
Germany
MIC code
XSTU